
LIGHTAI

Release Date: January 08, 2025 08:00AM Eastern Standard Time

Cboe Canada Announces Public Listing of Diagnostic Software Company Light Al





TORONTO--(BUSINESS WIRE)--Cboe Canada Inc. ("Cboe Canada") is excited to welcome healthcare company Light AI Inc. ("Light AI") as they complete their public offering. The Vancouver-based company produces diagnostic software to detect bacterial and viral infections and is available for trading on the Cboe Canada exchange under the symbol ALGO.

Light Al's patented diagnostic software uses Artificial Intelligence algorithms to analyze smartphone images for identifying Strep A infections without the use of traditional, in-person methods of diagnosis. In pre-FDA validation studies, Light Al's algorithm accurately diagnosed Strep A approximately 97% of the time, on par with the standard swab culture that is currently used for diagnoses.

Light Al's CFO, Darren Tindale, commented "We are thrilled to announce our successful listing on Cboe Canada. This milestone marks a significant achievement in our growth strategy, enhancing liquidity and visibility for our investors. By joining one of the leading stock exchanges, we aim to further strengthen our market presence and unlock greater value for shareholders. We look forward to the exciting opportunities this listing will bring as we continue to execute on our long-term objectives.

Investors can trade shares of ALGO through their usual investment channels, including discount brokerages and full-service dealers.

"We commend Light AI on their innovative work using artificial intelligence to provide much-needed advancements in the healthcare space," noted Tanya Rowntree, Head of Listings at Cboe Canada. "It is always a pleasure to support a company with a positively impactful mission like Light AI and we look forward to facilitating the next steps in their capital markets journey through enhanced investor exposure, greater access to liquidity, and a solutions-oriented approach to service. Welcome to Cboe!"

Cboe Canada is home to some of the most innovative Canadian and international growth companies, ETFs from Canada's largest ETF issuers, and the entire suite of Canadian Depositary Receipts (CDRs). Cboe consistently facilitates 15% of all volume traded in Canadian listed securities.

About Choe Canada

Cboe Canada is Canada's Tier 1 stock exchange providing a best-in-class listing experience for Issuers that are shaping the economies of tomorrow. Fully operational since 2015, Cboe Canada lists companies and investment products seeking an internationally recognized stock exchange that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data.

Cboe Canada is part of Cboe Global Markets, the leading securities and derivatives exchange for the world stage. With exchanges in North America, Europe and Asia Pacific, Cboe is harnessing its global

network to equip Issuers with the capital markets solutions they're looking for: a best-in-class listing experience, greater visibility, secondary liquidity, and better access to global capital.

About Light Al

Light AI Inc. is a healthcare company focused on developing artificial intelligence health diagnostic applications. Light AI is developing a technology platform which represents the next generation diagnostics: it applies AI algorithms to smartphone images—starting with images of StrepA—to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5B smartphones that exist in the world today.

In pre-FDA validation studies, Light Al's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved an accuracy rate of over 96%, with a 97% accuracy rate that is comparable to the "Gold Standard" swab culture currently used for diagnosing GAS. Furthermore, the algorithm attained a Negative Predictive Value (NPV) of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection.

Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding \$1 trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs.

Light Al's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.



Contact Us

<u>info@light.ai</u>